Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ragole

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Neurology and Neurosurgery|July 6, 2020
Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patientsChafic Karam, Thomas Ragole, Orly Moshe-Lilie, et al.
Journal of Neurology|May 14, 2020
Screening for genetic mutations in patients with neuropathy without definite etiology is usefulBraden Vogt, Nizar Chahin, Wojciech Wiszniewski, et al.
Neurology|July 16, 2020
Nusinersen in adult patients with spinal muscular atrophy: Observations from a single centerOrly Moshe-Lilie, Amy Visser, Nizar Chahin, et al.
Journal of the Neurological Sciences|June 5, 2020
Diagnosis of paraproteinemic neuropathy: Room for improvementChafic Karam, Orly Moshe-Lilie, Nizar Chahin, et al.
BMC Neurology|February 28, 2021
CIDP mimics: a case seriesOrly Moshe-Lilie, Erik Ensrud, Thomas Ragole, et al.
Biological Psychiatry|November 17, 2009
5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stressJohn P Christianson, Thomas Ragole, Jose Amat, et al.
Biological Psychiatry|June 21, 2011
Safety signals mitigate the consequences of uncontrollable stress via a circuit involving the sensory insular cortex and bed nucleus of the stria terminalisJohn P Christianson, Joshua H Jennings, Thomas Ragole, et al.
Plos One|December 11, 2025
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history studyKarlien Mul, Kate Eichinger, Man Hung, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Journal of Neuromuscular Diseases|February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH studyNicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Neurology and Neurosurgery|July 6, 2020
Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patientsChafic Karam, Thomas Ragole, Orly Moshe-Lilie, et al.
Journal of Neurology|May 14, 2020
Screening for genetic mutations in patients with neuropathy without definite etiology is usefulBraden Vogt, Nizar Chahin, Wojciech Wiszniewski, et al.
Neurology|July 16, 2020
Nusinersen in adult patients with spinal muscular atrophy: Observations from a single centerOrly Moshe-Lilie, Amy Visser, Nizar Chahin, et al.
Journal of the Neurological Sciences|June 5, 2020
Diagnosis of paraproteinemic neuropathy: Room for improvementChafic Karam, Orly Moshe-Lilie, Nizar Chahin, et al.
BMC Neurology|February 28, 2021
CIDP mimics: a case seriesOrly Moshe-Lilie, Erik Ensrud, Thomas Ragole, et al.
Biological Psychiatry|November 17, 2009
5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stressJohn P Christianson, Thomas Ragole, Jose Amat, et al.
Biological Psychiatry|June 21, 2011
Safety signals mitigate the consequences of uncontrollable stress via a circuit involving the sensory insular cortex and bed nucleus of the stria terminalisJohn P Christianson, Joshua H Jennings, Thomas Ragole, et al.
Plos One|December 11, 2025
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history studyKarlien Mul, Kate Eichinger, Man Hung, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Journal of Neuromuscular Diseases|February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH studyNicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Pageof 2